

## June 2020—Gordon Dunn Report

ASCO 2020: Blood Test Predicts Response to Prostate Cancer Treatment:

<https://www.pcf.org/news/asco-2020-blood-test-predicts-response-to-prostate-cancer-treatment/>

Lynparza approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer:

<https://www.pcf.org/news/lymparza-approved-in-the-us-for-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer/>

Rubraca® (Rucaparib) Approved In The U.S. As Monotherapy Treatment For Patients With BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (MCRPC) Who Have Been Treated With Androgen Receptor-Directed Therapy And A Taxane-Based Chemotherapy:

<https://www.pcf.org/news/fda-approves-rucaparib-for-treatment-of-advanced-prostate-cancer/>